about
Topical interventions for genital lichen sclerosusBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice.Safety of treatment with biologics for psoriasis in daily practice: 5-year data.The safety of infliximab infusions in the community settingEffective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaquesGoeckerman therapy for the treatment of eczema: a practical guide and review of efficacy.Challenges for synthesising data in a network of registries for systemic psoriasis therapies.Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.Ustekinumab: differential use in psoriasisUnusual case of B cell lymphoma after immunosuppressive treatment for psoriasisEvidence-based (S3) Guideline on (anogenital) Lichen sclerosus.Psoriatic disease and tuberculosis nowadays.Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.CCR6 as a possible therapeutic target in psoriasis.Management of itch in atopic dermatitis.Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.Cancer risk in immune-mediated inflammatory diseases (IMID).Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.Psoriasis and its treatment with adalimumab.Targeting IL-23 in human diseases.Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.Focus on skin cancer association and progression under TNF antagonist therapy.Multiple eruptive squamous cell carcinoma in a patient with chronic plaque psoriasis on adalimumab.Diagnosis and treatment of pediatric psoriasis: current and future.Methotrexate-induced acute leukemia: report of three cases and review of the literature.Phototherapy, psoriasis, and the age of biologics.Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis.Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes.The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature.Five-year experience with infliximab: Follow up of the product familiarisation program.Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain.A dermatologist guide to immunogenicityBiologics in dermatology: adverse effects.Nodal Melanoma Metastasis under Infliximab Therapy in a Patient with Nevoid Melanoma First Misdiagnosed as Benign Nevus: A Potentially Dangerous Diagnostic Pitfall in the Era of Biologic TherapiesPsoriatic arthritis with acral lentiginous melanoma: role for methotrexate?Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
P2860
Q24234187-CA492209-4B07-4477-A24B-0E678CB81A9AQ30412650-560C4759-9716-4F31-9165-0752226F2540Q33687980-BB8CBF86-57C7-48CB-9485-D0C57643A7B3Q33854744-F53F2E18-BAA4-48C6-92DE-655A12E6C2ACQ33916750-AB27C594-CCA0-40D8-8CE3-AC3CE2ADD40FQ34200331-246721FF-B8DA-4066-BC1C-7792E18F05A2Q34204298-E3152F67-E29E-434D-8AC6-8E0FB4E98FADQ34296816-726A38F2-B155-494E-86E3-FD168F3A8B4AQ34449302-14BBD8CE-1A4C-4FCC-ACBA-599054339EA2Q35005664-79A597B3-9AE9-4A53-90F6-0D55A79FD762Q35096980-8EA69141-EFB0-4ABC-9FBA-3B82B602ED4CQ35501279-12687DC2-E3BA-4F28-8F55-A2F5CAF952FAQ35707399-D801430F-A366-4A50-96B1-32E75912A828Q35974892-4447317E-0E7F-4885-A397-C9CCE805C4BBQ36552806-EF01DEBC-841D-48EC-8A16-8CA04ACDDED6Q36738727-42203E13-9ACD-4E90-ABEF-0519BAC7EADEQ36980670-5005BBA8-5535-466C-9FBD-6C000293395DQ36991444-8F7C4102-36B2-4D21-9D66-ABEED5AA35F1Q37078893-9857D8B9-B316-40E8-A4F0-3CB8CDE5A63FQ37153407-00BD2100-9686-4596-BEAB-56A39563993AQ37600436-F4747085-092C-4085-A3C2-490B397C5DB7Q37676220-68126BA2-398F-40A8-85EB-CDFBC8E2CD45Q37763951-2A8EEC6B-F796-4A62-9F53-251F97FA6BCAQ37781378-C174E732-71DD-428E-8E94-D0765EFC6D87Q37898704-D815C615-D5FC-436F-A5EE-41F9D82B1915Q37901473-E6C7EBBB-66D6-4C50-B335-D45B35CB4038Q38023580-9F11EF60-E62E-4563-A014-387D818FD7C0Q38107168-718B8DE9-0B93-4A09-B673-185E61CE8C08Q38157860-067AC8F6-5C27-435A-95AF-B0B34C3B7E6DQ38169210-A4B4E0B6-A6BC-4A8D-93C8-C8E8BF659FB2Q38231348-1346E08E-311A-4026-BC89-D801E2738A56Q38602543-20A850F3-F083-4A62-9B2A-97346035FF4EQ38681514-2F5AD73E-3638-4BE9-8713-36650AF9D5D3Q38963492-706C25E5-9FDD-4A2A-AB7C-D77FE60F787DQ39227956-0D6088AB-4F69-4FE4-9094-63D6BA827305Q39297511-92B722F3-3641-40E6-8576-02BAFBD1A9A2Q41120913-FBEE3A27-C656-440B-BFDC-FF58E1271B53Q41857215-54952589-BDF0-46D0-9A25-F6EDC6263AD8Q42031314-42EF49D1-321F-474C-A479-B72648593FF5Q42240106-1C304881-F75B-4561-81AD-6314797AEAC6
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatments for psoriasis and the risk of malignancy.
@ast
Treatments for psoriasis and the risk of malignancy.
@en
Treatments for psoriasis and the risk of malignancy.
@nl
type
label
Treatments for psoriasis and the risk of malignancy.
@ast
Treatments for psoriasis and the risk of malignancy.
@en
Treatments for psoriasis and the risk of malignancy.
@nl
prefLabel
Treatments for psoriasis and the risk of malignancy.
@ast
Treatments for psoriasis and the risk of malignancy.
@en
Treatments for psoriasis and the risk of malignancy.
@nl
P2093
P1476
Treatments for psoriasis and the risk of malignancy.
@en
P2093
Jeffrey M Weinberg
Lily N Clark
Mark Lebwohl
Rita V Patel
P304
P356
10.1016/J.JAAD.2008.12.031
P407
P577
2009-04-02T00:00:00Z